Tag Archive for: enzalutamide
Real-World Studies Suggest Survival Advantage with Apalutamide in mCSPC Treatment
/in Retrospective studies/by MaxPhase 1/2 Trial: Targeting Resistance With SX-682 And Apalutamide or Enzalutamide
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final OS Analisys Confirms Talazoparib + Enzalutamide Effectiveness in mCRPC
/in Clinical Trial, Metastatic, Phase 3/by MaxPembrolizumab Plus Enzalutamide Therapy Shows No Benefit in Metastatic Castration-Resistant Prostate Cancer Trial
/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 1 Trial: The COSMYC Trial, ZEN-3694 Combination With BAT
/in Clinical Trial, Metastatic, Phase 2/by MaxEnzalutamide Boosts PSA Control in High-Risk Prostate Cancer: Insights from the EMBARK Trial
/in Post-hoc, Retrospective studies/by MaxTalazoparib Plus Enzalutamide in HRR-Deficient mCRPC: Final Overall Survival Results from TALAPRO-2
/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- The MOMENT Trial: Mevrometostat Plus Enzalutamide in Post‑ARPI, Pre‑Abiraterone mCRPC May 29, 2026
- Phase 3 CaBRA Trial: Adding Carboplatin for mHSPC With BRCA Mutations or Neuroendocrine Phenotype May 29, 2026
- Scientists Identify SIRT1 as a Driver of Neuroendocrine Prostate Cancer May 29, 2026
- B7-H3 ADC YL201 Delivers Encouraging Results in Advanced mCRPC May 26, 2026